HOME >> BIOLOGY >> NEWS
Bacteria's natural foe fights drug-resistant infections

in nursing homes and day-care centers, where drug-resistant strains thrive.

Until now, there has been no strategy to remove the reservoir of S. pneumoniae from the noses and throats of humans. Yet, this "home base" provides an excellent target for controlling infections.

"This enzyme will kill pneumococci on mucous membranes within seconds," says Jutta Loeffler, M.D., first author of the paper and a postdoctoral fellow at Rockefeller. "By treating individuals carrying this bacterium with the enzyme, you could significantly reduce the reservoir of these bugs in the population and consequently reduce infection rates."

Such a decline in the number of worldwide infections would lessen the need for traditional antibiotics and subsequently ease the mounting drug-resistance problem.

Bacteriophage, or phage, can be found just about anywhere: in sewage and soil and any other locations where bacteria are found. As part of their normal lifecycle, these tiny viruses infect, replicate, then burst out of bacteria before infecting their next host.

Special phage enzymes, which punch holes in the bacterial cell wall, ensure the phage a rapid exit; without this outer layer of protection the bacteria essentially cannot hold themselves together, and, they explode.

Fischetti discovered that the phage enzymes also work when applied to the outside of the bacterial cells: by adding a few drops of phage enzyme to a test tube of millions of bacteria, he found that he could kill nearly all of them within a few seconds.

Because phage enzymes are specific for the species or strain of bacterium from which they were produced, cultivating a tailor-made killer for any bacterium of interest may be possible. Last February, for example, Fischetti and colleagues reported the isolation of a phage enzyme specific for Group A streptococci, an infectious pathogen that causes strep throat and flesh-eating disease. Human clinical trials testing the
'"/>

Contact: Whitney Clavin
clavinw@rockefeller.edu
212-327-7900
Rockefeller University
6-Dec-2001


Page: 1 2 3 4

Related biology news :

1. Bacterias iron-absorbing mechanisms may open gates for new types of antibiotics
2. Posters highlight water, energy and other natural resource research
3. Hunting illusive signs of natural selection
4. University of Arizona licenses patent for natural fungicide
5. Improving crops without genetic modification natural variation holds the key
6. Using statistics to decipher secrets of natural mutation
7. New designed paclitaxel analog kills more cancer cells than natural product
8. After natural disasters, the risk of infection, epidemics from dead bodies is negligible
9. Pearly mussels: One of North Americas natural jewels is disappearing
10. Unnatural light-dark cycles expose duelling circadian clocks
11. St. Jude researchers create image of enzyme that orchestrates natural genetic engineering

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
Cached News: